KOSPI holds near 5,859 in a selective risk-on session; telecom infra and semis lead while bio lags. Smart money screener surfaces SK Hynix, RFHIC, and more.
Deep dive into APR (278470.KQ), the Korean company behind Medicube and AGE-R devices — a rare growth+profitability combination in global beauty tech.
NextBiomedical investment analysis. Nexpowder hemostatic agent in commercialization phase across 30+ countries via Medtronic. Nexphere-F absorbable embolization microsphere in US pivotal trial with FDA Breakthrough Device Designation. 2025 revenue KRW 16.5B, OP loss KRW 735M. HS code export data-based Q1 2026 estimates and analyst target price reverse-engineering.
Deep-dive on Pharma Research Products (214450.KQ), the Korean KOSDAQ company behind Rejuran PDRN skin boosters riding the global K-beauty aesthetics wave.
Deep-dive into Samsung Electronics (005930.KS): HBM memory, Galaxy, and foundry ambitions—what global investors need to know about Korea's tech crown jewel.
Deep-dive on SK hynix (000660.KS): how the world's HBM leader became indispensable to AI infrastructure — and what it means for global investors.
KOSPI faces risk-off pressure as foreign outflows hit records. We break down AI semiconductor plays and Korea market themes for April 2026.
KOSPI closed in selective risk-on mode on April 10, with Samsung Electro-Mechanics surging 9.5% and telecom infrastructure stocks driving the day's narrative.
KOSPI ends April 9 in mild risk-off mode as Samsung Electronics slips 3%, overshadowing strength in telecom and EPC plays. Key levels to watch tomorrow.
APR deep analysis. Market cap KRW 12T+ surpassing Amorepacific and LG H&H to become Korea's #1 beauty company. Medicube revenue KRW 1.4T, AGE-R 6M+ cumulative units, 2026 revenue guidance KRW 2.1T. Strong fundamentals and chart, but not cheap.